Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome

NCT01371565 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.

NCT NCT01371565
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01371565 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome
Lead sponsor
Corcept Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2010
Completion date
September 30, 2012
Enrollment
4 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cushing's disease, cushing's syndrome